The cost effectiveness of licensed oromucosal midazolam (Buccolam ®) for the treatment of children experiencing acute epileptic seizures: An approach when trial evidence is limited

Pediatric Drugs

Volumn 15, Issue 2, 2013, Pages 151-162

  Lee, Dawn ^a   Gladwell, Daniel ^a   Batty, Anthony J ^a   Brereton, Nic ^a   Tate, Elaine ^b  

^a BRESMED   (United Kingdom)

^b ANIMAL HEALTH TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAZEPAM; MIDAZOLAM;

ARTICLE; CLINICAL PRACTICE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SEIZURE; UNITED KINGDOM;

ACUTE DISEASE; ADMINISTRATION, BUCCAL; ADMINISTRATION, RECTAL; CHILD; COST-BENEFIT ANALYSIS; DECISION TREES; DIAZEPAM; DRUG APPROVAL; EPILEPSY; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MIDAZOLAM; QUALITY OF LIFE; STANDARD OF CARE;

EID: 84877058322     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0009-5     Document Type: Article

References (28)

1. ® 2.5 mg oromucosal solution: summary of product characteristics [online]. http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/002267/WC500112310. pdf. Accessed 30 Aug 2012.
2. Chin RF, Neville BG, Peckham C, Bedford H, Wade A, Scott RC. Incidence, cause, and short-term outcome of convulsive status epilepticus in childhood: prospective population-based study. Lancet. 2006;368(9531):222-9.
3. Raspall-Chaure M, Chin RF, Neville BGR, Scott RC. Outcome of paediatric convulsive status epilepticus: a systematic review. Lancet Neurol. 2006;5(9):769-79.
4. Forsgren L, Beghi E, Oun A, Sillanpaa M. The epidemiology of epilepsy in Europe: a systematic review. Eur J Neurol. 2005;12(4):245-53.
5. SEIN, WHO Collaborating Centre for Research, Training and Treatment in Epilepsy, WHO headquarters, ILAE/IBE/WHO Global Campaign Against Epilepsy. Epilepsy in the WHO European region: fostering epilepsy care in Europe [online]. http://www.ibe-epilepsy.org/downloads/EUROReport160510.pdf. Accessed 30 Aug 2012.
6. World Health Organization. Epilepsy fact sheet No 999 (01/2009) [online]. http://www.who.int/mediacentre/factsheets/fs999/en/index.html. Accessed 15 Aug 2012.
7. Joint Epilepsy Council. Epilepsy prevalence, incidence and other statistics [online]. http://www.epilepsyscotland.org.uk/pdf/Joint-Epilepsy- Council-Prevalence-and-Incidence-September-11-(3).pdf (2011). Accessed 30 Aug 2012.
8. Pellock JM. Overview: definitions and classifications of seizure emergencies. J Child Neurol. 2007;22(5 suppl):9S-13S.
9. Klimach VJ; Epic Clinical Network. The community use of rescue medication for prolonged epileptic seizures in children. Seizure. 2009;18(5):343-6.
10. Scott RC, Besag MF, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999;353(9153):623-6.
11. Camfield CS, Camfield PR, Smith E, Dooley JM. Home use of rectal diazepam to prevent status epilepticus in children with convulsive disorders. J Child Neurol. 1989;4(2):125-6.
12. O'Dell C, Shinnar S, Ballaban-Gil KR, et al. Rectal diazepam gel in the home management of seizures in children. Pediatr Neurol. 2005;33(3):166-72.
13. Delphi survey of the current clinical practice in Wales for the treatment of prolonged acute convulsive seizures in children and adolescents. Brussels: ViroPharma SPRL-BVBA; 2011 (Data on File).
14. Wilson MT, Macleod S, O'Regan ME. Nasal/buccal midazolam use in the community. Arch Dis Child. 2004;89(1):50-1.
15. Chattopadhyay A, Morris B, Blackburn L, et al. Buccal midazolam and rectal diazepam for epilepsy. Lancet. 1999;353(9166):1798.
16. Pharmaceutical Services Negotiating Committee. Unlicensed specials and imports FAQs [online]. http://www.psnc.org.uk/publications-detail.php/285/ unlicensed-specials-and-imports-guidance (2011). Accessed 30 Aug 2012.
17. General Medical Council. Good Practice in Prescribing Medicines [online]. Available from URL: http://www.gmc-uk.org/guidance/ethical-guidance/ prescriptions-faqs.asp (2008). Accessed 30 Aug 2012.
18. ®) SMC No. (757/12): ViroPharma Ltd [online]. http://www.scottishmedicines.org.uk/SMC-Advice/Advice/757-12-midazolam-Buccolam- oromucosal-solution/midazolam-Buccolam-oromucosal-solution (2012). Accessed 24 Jan 2013.
19. ®). Submission by ViroPharma Ltd [online]. http://www.wales.nhs.uk/sites3/Documents/371/ midazolam%20(Buccolam)%20FAR%20(W).pdf (2012). Accessed 30 Aug 2012.
20. McIntyre J, Robertson S, Norris E, et al. Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial. Lancet. 2005;366(9481):205-10.
21. Mpimbaza A, Ndeezi G, Staedke S, et al. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics. 2008;121(1):e58-64.
22. McMullan J, Sasson C, Pancioli A, Silbergleit R. Midazolam versus diazepam for the treatment of status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med. 2010;17(6):575-82.
23. Patient Survey Wales: Epilepsy rescue medication and your child. ViroPharma SPRL-BVBA; 2011 (Data on File).
24. Chin RF, Neville BG, Peckham C, et al. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol. 2008;7(3):696-703.
25. NHS Business Services Authority. Electronic drug tariff [online]. http://www.ppa.org.uk/edt/January-2013/mindex.htm. Accessed 24 Jan 2013.
26. Joint Formulary Committee. British National Formulary 64 [online]. http://www.medicinescomplete.com/mc/bnf/current/ (2011). Accessed 24 Jan 2013.
27. Department of Health. NHS Reference Costs 2011-2012 [online]. http://www.dh.gov.uk/health/2012/11/2011-12-reference-costs/. Accessed 24 Jan 2013.
28. Strzelczyk A, Nickolay T, Bauer S, Haag A, Knake S, Oertel WH et al. Evaluation of health-care utilization among adult patients with epilepsy in Germany. Epilepsy Behav. 2012;23(4):451-7.